If female and of childbearing potential, is willing to use medically acceptable contraceptive measures for the duration of the study; acceptable methods of contraception include () surgical sterilization (such as tubal ligation or hysterectomy), () approved hormonal contraceptives (such as birth control pills, patches, implants or injections), () barrier methods (such as condom or diaphragm) used with a spermicide, or () an intrauterine device (IUD); contraceptive measures such as rhythm method or Plan B, sold for emergency use after unprotected sex, are not acceptable methods for routine use
For women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to the start of the study; women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for the duration of the study; medically acceptable contraceptives include: () surgical sterilization (such as a tubal ligation or hysterectomy), () approved hormonal contraceptives (such as birth control pills, patches, implants or injections), () barrier methods (such as a condom or diaphragm) used with a spermicide, or () an intrauterine device (IUD); contraceptive measures such as Plan B (TM), sold for emergency use after unprotected sex, are not acceptable methods for routine use; if you do become pregnant during this study or if you have unprotected sex, you must inform your study physician immediately
For men who are sexually active, must agree to use a two medically acceptable forms of birth control (one of which must include a condom as a barrier method of contraception) in order to be in this study; medically acceptable contraceptives include: () surgical sterilization (such as a vasectomy), or () a condom used with a spermicide; contraceptive measures such as Plan B (TM), sold for emergency use after unprotected sex, are not acceptable methods for routine use; men must also agree to inform their partner of the potential for harm to an unborn child; she should know that if pregnancy occurs, the subject will need to report it to the study doctor, and she should promptly notify her doctor; the study doctor will ask if the subjects partner is willing to provide updates on the progress of the pregnancy and its outcome; if the subjects partner agrees, this information will be provided to Pfizer, Inc. for safety monitoring follow-up
Pregnant or breast-feeding; female patients of child-bearing potential or female sexual partners (who are of child-bearing potential) of male patients must use at least one of the following methods of medically acceptable contraceptives: approved hormonal contraceptives (such as birth control pills, patches, implants or infusions), an intrauterine device (IUD), or a barrier method of contraception (such as a condom or diaphragm) used with spermicide; there should be no risk of transmission of a mother to her fetus after receiving intracranial PVSRIPO; as such, patients who become pregnant after receiving PVSRIPO will continue to be monitored in the same manner, i.e. per protocol, unless the assessment is contraindicated during pregnancy; partners who become pregnant will sign a Pregnant Partner Information Form and information regarding the pregnancy and its outcome may be collected
Females who are pregnant or breast-feeding; female patients of child-bearing potential or female sexual partners (who are of child-bearing potential) of male patients must use at least one of the following methods of medically acceptable contraceptives: approved hormonal contraceptives (such as birth control pills, patches, implants or infusions), an intrauterine device (IUD), or a barrier method of contraception (such as a condom or diaphragm) used with spermicide; as such, patients who become pregnant after receiving PVSRIPO will continue to be monitored in the same manner, i.e. per protocol, unless the assessment is contra-indicated during pregnancy; partners who become pregnant will sign a Pregnant Partner Information Form and information regarding the pregnancy and its outcome may be collected
Women of child-bearing potential must consent to use adequate contraception during the course of the study: () surgical sterilization (such as a tubal ligation or hysterectomy), () barrier methods (such as a condom or diaphragm) used with a spermicide, or () an intrauterine device (IUD); contraceptive measures such as Plan B (TM), sold for emergency use after unprotected sex, are not acceptable methods for routine use
Women of child-bearing potential must consent to use adequate contraception during the course of the study; female subjects must agree to use a medically acceptable contraceptives including: () surgical sterilization (such as a tubal ligation or hysterectomy), () approved hormonal contraceptives (such as birth control pills, patches, implants or injections), () barrier methods (such as a condom or diaphragm) used with a spermicide, or () an intrauterine device (IUD); contraceptive measures such as Plan B (TM), sold for emergency use after unprotected sex, are not acceptable methods for routine use
Pregnant, breast-feeding or of childbearing potential and is not protected by a medically acceptable, effective method of birth control while enrolled in the study; medically acceptable contraceptives include: () approved hormonal contraceptives (such as birth control pills, patches, implants or injections), () barrier methods (such as a condom or diaphragm) used with a spermicide, or () an intrauterine device (IUD); contraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use
Any of the following:\r\n* Pregnant women\r\n* Nursing women\r\n* Women of child-bearing potential must agree to use two forms of adequate contraception from time of initial consent, for the duration of study participation, and for >=  months after the last dose of study drug; medically acceptable contraceptives include: () surgical sterilization (such as a tubal ligation or hysterectomy), () approved hormonal contraceptives (such as birth control pills, patches, implants or injections), () barrier methods (such as a condom or diaphragm) used with a spermicide, or () an intrauterine device (IUD); contraceptive measures such as Plan B, sold for emergency use after unprotected sex, are not acceptable methods for routine use; postmenopausal woman must have been amenorrheic for at least  years to be considered of non-childbearing potential; sexually active men must use at least one form of adequate contraception from time of initial consent, for the duration of study participation, and for >=  months after the last dose of study drug
Patients with female partners of childbearing potential must use at least one form of Investigator-approved contraception while on-study and for  days after their last administration of study investigational therapy. Acceptable birth control options include: a) surgical sterilization (subject and/or subject's partner), b) approved hormonal contraceptives or therapies (such as birth control pills, Depo-Provera, or Lupron Depot), c) barrier methods (such as a condom or diaphragm) used with a spermicide, and d) an intrauterine device (IUD).
Women of child bearing years must have a negative pregnancy test (serum or urine) within  week of study entry; men and women of reproductive potential must agree to use an effective contraceptive method including one of the following: surgical sterilization (tubal ligation for women or vasectomy for men); approved hormonal contraceptives (such as birth control pills, Depo-Provera or Lupron Depro); barrier methods (such as condom or diaphragm) used with a spermicide cream or an intrauterine device (IUD)
Females of childbearing potential must be willing to abstain from heterosexual activity or to use two effective methods of contraception from the time of informed consent until  months after the last dose of mirvetuximab soravtansine\r\n* Medically acceptable contraceptives include:\r\n** Surgical sterilization (such as a tubal ligation or hysterectomy)\r\n** Approved hormonal contraceptives (such as birth control pills, patches, implants or injections)\r\n** Barrier methods (such as a condom or diaphragm) used with a spermicide\r\n** An intrauterine device (IUD)\r\n* Contraceptive measures such as Plan B are not acceptable
Pregnant, breast-feeding or of childbearing potential and is not protected by a medically acceptable, effective method of birth control while enrolled in the study. Medically acceptable contraceptives include: () approved hormonal contraceptives (such as birth control pills, patches, implants or injections), () barrier methods (such as a condom or diaphragm) used with a spermicide, or () an intrauterine device (IUD). Contraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use.
Pregnant, breast-feeding or of childbearing potential and is not protected by a medically acceptable, effective method of birth control while enrolled in the study; medically acceptable contraceptives include: () approved hormonal contraceptives (such as birth control pills, patches, implants or injections), () barrier methods (such as a condom or diaphragm) used with a spermicide, or () an intrauterine device (IUD); contraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use
Pregnant, breast-feeding or of childbearing potential and is not protected by a medically acceptable, effective method of birth control while enrolled in the study; medically acceptable contraceptives include: () approved hormonal contraceptives (such as birth control pills, patches, implants or injections, () barrier methods (such as condom or diaphragm) used with a spermicide, or () an intrauterine device (IUD); contraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use